Could a memory drug fight prostate cancer? small trial aims to find out
NCT ID NCT07164794
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 2 trial tests whether memantine hydrochloride, a drug used for Alzheimer's, can help control advanced prostate cancer that has stopped responding to standard hormone therapy. Fifteen men with metastatic castration-resistant prostate cancer will take memantine alongside their usual treatment. Researchers will track how long the disease stays under control and whether PSA levels drop.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
memantine hydrochloride
What this could lead to
If it works, this could point toward a new way to slow advanced prostate cancer by adding a common Alzheimer's drug to standard care.
What could go wrong
This is a very early, small study with only 15 people. It may not show clear benefit, and memantine is not proven for cancer. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.